Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment
Tuesday, November 25, 2025, 10:21 am / permalink 16294 / 5 stories in 3 months
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)
GLP‑1 drugs associated with lower addiction risk in large study (4 days)
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (8 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.